Compound Information | SONAR Target prediction | Name: | PERPHENAZINE | Unique Identifier: | SPE01503934 | MolClass: | Checkout models in ver1.5 and ver1.0 | Molecular Formula: | | Molecular Weight: | 377.763 g/mol | X log p: | 16.257 (online calculus) | Lipinksi Failures | 1 | TPSA | 35.02 | Hydrogen Bond Donor Count: | 0 | Hydrogen Bond Acceptors Count: | 4 | Rotatable Bond Count: | 6 | Canonical Smiles: | OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1 | Source: | synthetic | Therapeutics: | antipsychotic | Generic_name: | Perphenazine | Chemical_iupac_name: | 2-[4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]piperazin-1-yl]ethanol | Drug_type: | Approved Drug | Pharmgkb_id: | PA450882 | Kegg_compound_id: | C07427 | Drugbank_id: | APRD00429 | Melting_point: | 97 oC | H2o_solubility: | 28.3 mg/L | Logp: | 4.176 | Isoelectric_point: | 7.94 | Cas_registry_number: | 58-39-9 | Mass_spectrum: | http://webbook.nist.gov/cgi/cbook.cgi?Spec=C58399&Index=0&Type=Mass&Large=on | Drug_category: | Antipsychotics; Phenothiazines; Dopamine Antagonists; ATC:N05AB03 | Indication: | For use in the management of the manifestations of psychotic disorders and for the control of severe nausea and vomiting in adults. | Pharmacology: | Perphenazine is a piperazinyl phenothiazine, acts on the central nervous system, and has a greater behavioral potency than other phenothiazine derivatives whose side chains do not contain a piperazine moiety. It is a member of a class of drugs called phenothiazines, which are dopamine D1/D2 receptor antagonists. Perphenazine is 10 to 15 times as potent as chlorpromazine; that means perphenazine is a highly potent antipsychotic. In equivalent doses it has approximately the same frequency and severity of early and late extrapypramidal side-effects compared to Haloperidol. | Mechanism_of_action: | Binds to the dopamine D1 and dopamine D2 receptors and inhibits their activity. The mechanism of the anti-emetic effect is due predominantly to blockage of the dopamine D2 neurotransmitter receptors in the chemoreceptor trigger zone and vomiting centre. Perphenazine also binds the alpha andrenergic receptor. This receptor-s action is mediated by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. | Organisms_affected: | Humans and other mammals |
Species: |
4932 |
Condition: |
WHI5 |
Replicates: |
2 |
Raw OD Value: r im |
0.7113±0.013435 |
Normalized OD Score: sc h |
0.9905±0.00947544 |
Z-Score: |
-0.1994±0.299785 |
p-Value: |
0.835378 |
Z-Factor: |
-8.4887 |
Fitness Defect: |
0.1799 |
Bioactivity Statement: |
Nonactive |
Experimental Conditions | | Library: | SPECMTS3 | Plate Number and Position: | 20|E5 | Drug Concentration: | 50.00 nM | OD Absorbance: | 600 nm | Robot Temperature: | 26.00 Celcius | Date: | 2008-09-16 YYYY-MM-DD | Plate CH Control (+): | 0.041749999999999995±0.00056 | Plate DMSO Control (-): | 0.6995749999999998±0.01500 | Plate Z-Factor: | 0.9404 |
| png ps pdf |
DBLink | Rows returned: 6 | |
4748 |
2-[4-[3-(2-chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethanol |
74835 |
2-[4-[3-(2-chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethanol dihydrochloride |
168090 |
2-[4-[3-(2-chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethanol hydrochloride |
213548 |
2-[4-[3-(2-chlorophenothiazin-10-yl)propyl]-1,4-dimethyl-2,3,5,6-tetrahydropyrazin-1-yl]ethanol diiodide |
213549 |
2-[4-[3-(2-chlorophenothiazin-10-yl)propyl]-1,4-dimethyl-2,3,5,6-tetrahydropyrazin-1-yl]ethanol |
4282573 |
2-[4-[3-(2-chlorophenothiazin-10-yl)propyl]-2,3,5,6-tetrahydropyrazin-1-yl]ethanol |
internal high similarity DBLink | Rows returned: 1 | |
active | Cluster 17541 | Additional Members: 13 | Rows returned: 3 | |
|